Avalo is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.
Company profile
Ticker
AVTX
Exchange
Website
CEO
Michael F. Cola
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cerecor Inc.
SEC CIK
Corporate docs
Subsidiaries
Medgenics Medical (Israel) Ltd. • Aevi Genomic Medicine Europe ...
AVTX stock data
Latest filings (excl ownership)
8-K
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
17 Jan 23
8-K
Completion of Acquisition or Disposition of Assets
14 Nov 22
S-8
Registration of securities for employees
7 Nov 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
7 Nov 22
8-K
Other Events
16 Aug 22
8-K
Avalo Therapeutics Announces Board Changes
11 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
4 Aug 22
8-K
Entry into a Material Definitive Agreement
1 Aug 22
Latest ownership filings
4
Magnus Persson
3 Jan 23
4
June Sherie Almenoff
3 Jan 23
4
GARRY ARTHUR NEIL
12 Dec 22
4
GARRY ARTHUR NEIL
7 Oct 22
4
Christopher Ryan Sullivan
7 Oct 22
4
June Sherie Almenoff
3 Oct 22
4
GILLA KAPLAN
3 Oct 22
4
Magnus Persson
3 Oct 22
SC 13D/A
ARMISTICE CAPITAL, LLC
11 Aug 22
SC 13G/A
Caissa Capital Management ltd.
8 Aug 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 17.18 mm | 17.18 mm | 17.18 mm | 17.18 mm | 17.18 mm | 17.18 mm |
| Cash burn (monthly) | (no burn) | 4.56 mm | (no burn) | 4.07 mm | (no burn) | 3.33 mm |
| Cash used (since last report) | n/a | 17.79 mm | n/a | 15.89 mm | n/a | 12.97 mm |
| Cash remaining | n/a | -609.10 k | n/a | 1.29 mm | n/a | 4.20 mm |
| Runway (months of cash) | n/a | -0.1 | n/a | 0.3 | n/a | 1.3 |
Institutional ownership, Q3 2022
67.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 26 |
| Opened positions | 2 |
| Closed positions | 31 |
| Increased positions | 0 |
| Reduced positions | 24 |
| 13F shares | Current |
|---|---|
| Total value | 21.79 mm |
| Total shares | 6.32 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Armistice Capital | 3.96 mm | $13.16 mm |
| Caissa Capital Management | 798.26 k | $3.46 mm |
| Nantahala Capital Management | 547.81 k | $1.82 mm |
| Point72 Asset Management | 500.74 k | $1.66 mm |
| Vanguard | 221.98 k | $736.00 k |
| BLK Blackrock | 103.41 k | $343.00 k |
| Geode Capital Management | 51.42 k | $170.00 k |
| Millennium Management | 51.01 k | $169.00 k |
| GS Goldman Sachs | 35.64 k | $118.00 k |
| Assenagon Asset Management | 15.65 k | $52.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Dec 22 | June Sherie Almenoff | Stock Option Common Stock | Grant | Acquire A | No | No | 5.0401 | 410 | 2.07 k | 410 |
| 30 Dec 22 | Persson Magnus | Stock Option Common Stock | Grant | Acquire A | No | No | 5.0401 | 2,536 | 12.78 k | 2,536 |
| 9 Dec 22 | Neil Garry Arthur | Common Stock | Buy | Acquire P | No | No | 4.42 | 2,083 | 9.21 k | 9,220 |
| 5 Oct 22 | Christopher Ryan Sullivan | Stock Option Common Stock | Grant | Acquire A | No | No | 3.97 | 25,000 | 99.25 k | 25,000 |
| 5 Oct 22 | Neil Garry Arthur | Stock Option Common Stock | Grant | Acquire A | No | No | 3.97 | 75,000 | 297.75 k | 75,000 |
News
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
23 Jan 23
12 Health Care Stocks Moving In Monday's Intraday Session
23 Jan 23
Avalo Announces It Has Completed Targeted Enrollment Of 80 Patients In Phase 2 PEAK Trial Of AVTX-002 In Non-Eosinophilic Asthma
17 Jan 23
Looking Into Avalo Therapeutics's Return On Capital Employed
30 Nov 22
Recap: Avalo Therapeutics Q3 Earnings
7 Nov 22